Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review

被引:0
作者
Aaron S. Farberg
Alison L. Fitzgerald
Sherrif F. Ibrahim
Stan N. Tolkachjov
Teo Soleymani
Leah M. Douglas
Sarah J. Kurley
Sarah T. Arron
机构
[1] Baylor University Medical Center,Baylor Scott & White Health System
[2] Castle Biosciences,undefined
[3] Inc.,undefined
[4] University of Rochester,undefined
[5] Epiphany Dermatology,undefined
[6] University of California Los Angeles,undefined
[7] Baylor College of Medicine,undefined
[8] Peninsula Dermatology,undefined
来源
Dermatology and Therapy | 2022年 / 12卷
关键词
Cutaneous squamous cell carcinoma; Risk factors; Staging; Outcomes; Molecular prognostication;
D O I
暂无
中图分类号
学科分类号
摘要
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma. While the majority of cSCC tumors are resectable with clear margins by standard excision practices, some lesions exhibit high-risk factors for which there is evidence of their association with recurrence, metastasis, and disease-specific death. The most commonly used staging systems and guidelines in the USA for cSCC are based on these clinical and pathologic high-risk factors; however, these are limited in their ability to predict adverse events, thus posing a challenge for implementing risk-directed patient management. Since the development of local recurrence and/or metastasis has a profound impact on the survival of patients with cSCC, accurate identification of patients at high risk for poor outcomes is critical, potentially allowing for early and appropriate adjuvant therapy. This review summarizes the current cSCC literature with a focus on how differing clinical assessments within each of the five selected risk factors (perineural invasion, differentiation, depth of invasion, size, and location) can influence the evaluation of patient outcomes, along with summarizing the utility of staging and guidelines, and highlighting the potential for molecular tools to improve upon cSCC risk assessment.
引用
收藏
页码:267 / 284
页数:17
相关论文
共 230 条
  • [1] Lomas A(2012)A systematic review of worldwide incidence of nonmelanoma skin cancer Br J Dermatol 166 1069-1080
  • [2] Leonardi-Bee J(2016)Risk factors for cutaneous squamous cell carcinoma outcomes: a systematic review and meta-analysis JAMA Dermatol 152 419-428
  • [3] Bath-Hextall F(2013)Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012 J Am Acad Dermatol 68 957-966
  • [4] Thompson AK(2005)Mortality risk from squamous cell skin cancer J Clin Oncol 23 759-765
  • [5] Kelley BF(2019)Cutaneous squamous cell carcinoma Dermatol Clin 37 241-251
  • [6] Prokop LJ(2007)Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma J Invest Dermatol 127 1351-1357
  • [7] Karia PS(2014)Nonmelanoma skin cancer: disease-specific quality-of-life concerns and distress Oncol Nurs Forum 41 57-65
  • [8] Han J(2021)Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma J Am Acad Dermatol 84 361-369
  • [9] Schmults CD(2021)Performance of Salamanca refinement of the T3-AJCC8 versus the Brigham and Women's Hospital and Tübingen alternative staging systems for high-risk cutaneous squamous cell carcinoma J Am Acad Dermatol. 84 938-945
  • [10] Clayman GL(2021)Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion J Am Acad Dermatol S0190–9622 02799-2807